Aperio Appoints Cari Kniola Director of Corporate Strategy

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Today Aperio Clinical Outcomes announced the appointment of Cari Kniola who will serve as their Director of Corporate Strategy.

The company reports Kniola has over 20 years of clinical research experience in the medical device and pharma industries, ranging from a clinical research associate through project management of global studies at both sponsor companies and CROs. This experience is combined with an appreciation for Aperio’s culture and the need to preserve it as the company continues to grow and evolve. This strategic growth occurs as Aperio continues to match pace with a clinical research industry experiencing emerging technologies, novel treatments and an ever-changing regulatory landscape. Kniola will lead through oversight of proposal and marketing strategy, strategic business development and service partnerships.

Says Faye Woolf, Aperio’s Founder and CEO, “We want to make sure to continue to grow Aperio in a way that maximizes our potential while being true to who we are, all the while providing our services with the utmost quality and integrity. We are so fortunate to have Cari’s natural inclination towards strategy and creative solutions coupled with a vast background in the industry to ensure we maintain our core principles as Aperio makes its mark in the industry.”

“My entire career has been involved in clinical research, and I thrive on the creative process and seeing strategic visions come to fruition,” says Kniola. “I am excited to take both my ‘real world’ experience and my innate skills and use them together to help strategize the growth of Aperio. We have a team of people at Aperio who are passionate about what they do, with an amazing depth and breadth of experience in clinical development. With our high caliber teams, our culture of quality and transparency, and our ability to evolve as the industry evolves, the possibilities are limitless for Aperio’s continued growth as an agile and innovative CRO services provider.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.